• 

  'Arbitrary & discriminatory': Sonia Gandhi writes to PM Modi over new vaccine policy

  India | April 22, 2021 13:19 IST

  Sonia Gandhi has written a letter to Prime Minister Narendra Modi over new vaccine policy. She has described the government's policy as arbitrary and discriminatory.

• 

  COVID 19 latest update: Coronavirus vaccine Covaxin works against multiple variants of SARS-COV-2

  Health | April 22, 2021 10:24 IST

  Leading vaccine maker Bharat Biotech and the Indian Council of Medical Research (ICMR) announced interim results from phase 3 clinical trials of coronavirus Covaxin, which show 78 per cent overall clinical efficacy and 100 per cent efficacy against severe Covid-19.

• 

  Bihar announces free vaccination for all above 18 years of age

  India | April 21, 2021 20:41 IST

  Bihar government will run a free vaccination drive against coronavirus for people above 18 years of age, Bihar Chief Minister Nitish Kumar informed on Wednesday.

• 

  0.04 % tested Covid positive after second dose of Covaxin, 0.03% after Covishield: Govt data

  India | April 21, 2021 18:56 IST

  More than 21,000 people tested positive for COVID-19 after taking the first dose of either Covishield or Covaxin, while over 5,500 contracted the infection after taking the second dose, the Centre said on Wednesday. 

• 

  Covaxin 100% effective against severe COVID cases: ICMR

  India | April 21, 2021 18:27 IST

  India's indigenously developed Bharat Biotech's coronavirus vaccine — Covaxin — works against multiple variant of Covid19. According to the Indian Council of Medical Research (ICMR) study, COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well.

• 

  Covaxin neutralises double mutant strain of Covid-19: ICMR

  India | April 21, 2021 13:58 IST

  ICMR study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well.

• 

  'Understand India's pharmaceutical needs': US to consider lifting ban on vaccine raw material supply

  World | April 20, 2021 14:50 IST

  The Biden administration has conveyed to India that they understand India's pharmaceutical requirements and has promised to review embargo on Covid-19 vaccine raw material.

• 

  Govt to provide Rs 4,500 cr booster to SII, Bharat Biotech for ramping up Covid vaccine production

  India | April 20, 2021 12:30 IST

  COVID-19 vaccine: SII will supply 200 million doses and Bharat Biotech is to supply another 90 million doses to the government by July at a pre-agreed rate of Rs 150 per dose.  

• 

  Covaxin production to increase 10 times by September: Harsh Vardhan

  India | April 18, 2021 23:07 IST

  Union Health Minister Harsh Vardhan on Sunday said there will be a 10 times rise in Covaxin vaccine production by September while manufacture of remdesivir jabs, an anti-viral drug against COVID-19, will be doubled to 74.1 lakh each month by May.

• 

  Centre allows Mumbai-based Haffkine Institute to manufacture Covaxin

  India | April 16, 2021 10:20 IST

  The Centre has granted permission to Haffkine Institute, Mumbai to manufacture Bharat Biotech's Covid-19 vaccine Covaxin

• 

  No dearth of Covid-19 vaccine, ramping up Remdesivir production: Harsh Vardhan

  India | April 14, 2021 17:38 IST

  Currently, two Covid-19 vaccines -- Covaxin and Covishield are being used for inoculation in the country. India has just granted permission for emergency use of Russia's Sputnik V vaccine.

Advertisement
• 

  COVID-19 vaccines in India: In a nutshell

  India | April 13, 2021 22:21 IST

  The Drugs Control General of India has permitted emergency use of Covid vaccine Sputnik V with certain conditions, clearing the way for a third vaccine in addition to Covishield and Covaxin.

• 

  Centre fast-tracks approval for foreign-produced Covid-19 vaccines to push inoculation drive

  India | April 13, 2021 16:29 IST

  Two Covid-19 vaccines -- Covaxin and Covishield are being used for inoculation in India. India has just granted permission for emergency use of Russia's Sputnik V vaccine.

• 

  India to produce 850 Million Sputnik V doses annually: RDIF

  India | April 13, 2021 12:09 IST

  The Drug Controller General of India (DCGI) has registered the vaccine under the emergency use authorisation procedure.

• 

  Manish Sisodia takes first jab of COVID vaccine

  News | April 03, 2021 17:49 IST

  Delhi Deputy Chief Minister Manish Sisodia along with his wife Seema Sisodia took first shot of the COVID-19 vaccine at Maulana Azad Medical College.

• 

  DGCI grants approval for clinical trials for third dose of Covaxin

  India | April 02, 2021 13:03 IST

  The expert panel of India's drug regulator, DCGI, has permitted Bharat Biotech to give the third dose of Covaxin to a few volunteers in its clinical trials of the COVID-19 vaccine.

• 

  Third phase of Covid-19 vaccination for all above 45 years from today

  India | April 02, 2021 9:30 IST

  The third phase of Covid-19 vaccination drive will include those who are above 45 years. People can book an appointment for COVID-19 vaccination via CoWIN. Beneficiaries can also go for on-site registration.

• 

  India to focus on meeting domestic demand of Covid-19 vaccine, no expansion of exports

  India | March 25, 2021 9:24 IST

  India started supplying the vaccine doses to foreign countries on January 20. The first countries to receive such vaccines were from the neighbourhood.

• 

  Nepal grants emergency use approval to Bharat Biotech's Covaxin

  World | March 20, 2021 13:21 IST

  Bharat Biotech had applied for emergency use authorisation for its vaccine candidate, Covaxin, in Nepal on January 13. Covaxin demonstrated an interim vaccine efficacy of 81 per cent in the Phase 3 clinical trials India.

• 

  Ambassador of Paraguay to India requests 'COVAXIN' supply

  News | March 17, 2021 22:40 IST

  Ambassador of Paraguay to India, Fleming Raul Duarte requested for supply of COVAXIN, the COVID-19 vaccine by Hyderabad-based 'Bharat Biotech' and also heaped praises on India for its vaccine diplomacy.